Modulation of paraoxonase 1 and protein N-homocysteinylation by leptin and the synthetic liver X receptor agonist T0901317 in the rat

Journal of Endocrinology

Volumn 204, Issue 2, 2010, Pages 191-198

  Bełtowski, Jerzy ^a   Wójcicka, Grazyna ^a   Jakubowski, Hieronim ^b,c  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^c POZNA UNIVERSITY OF LIFE SCIENCES   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

APOCYNIN; ARYLDIALKYLPHOSPHATASE 1; HOMOCYSTEINE THIOLACTONE; ISOPROSTANE; LEPTIN; LIVER X RECEPTOR AGONIST; N (2,2,2 TRIFLUOROETHYL) N [4 (2,2,2 TRIFLUORO 1 HYDROXY 1 TRIFLUOROMETHYLETHYL)PHENYL]BENZENESULFONAMIDE; PLASMA PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; HYPERLEPTINEMIA; MALE; METABOLIC SYNDROME X; METABOLISM; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT; SHAM FEEDING;

ACETOPHENONES; ANIMALS; ARYLDIALKYLPHOSPHATASE; BLOOD PROTEINS; HOMOCYSTEINE; HYDROCARBONS, FLUORINATED; LEPTIN; LIVER; MALE; NADPH OXIDASE; ORPHAN NUCLEAR RECEPTORS; OXIDATIVE STRESS; RATS; RATS, WISTAR; SULFONAMIDES;

EID: 75149156242     PISSN: 00220795     EISSN: 14796805     Source Type: Journal    
DOI: 10.1677/JOE-09-0298     Document Type: Article

References (56)

1. Ayub A, Mackness MI, Arrol S, Mackness B, Patel J & Durrington PM 1999 Serum paraoxonase after myocardial infarction. Arteriosclerosis, Thrombosis, and Vascular Biology 19 330-335.
2. Bajnok L, Seres I, Varga Z, Jeges S, Peti A, Karanyi Z, Juhasz A, Csongradi E, Mezosi E, Nagy EV et al. 2007 Relationship of endogenous hyperleptinemia to serum paraoxonase 1, cholesteryl ester transfer protein, and lecithin cholesterol acyltransferase in obese individuals. Metabolism 56 1542-1549.
3. Balogh Z, Fóris G, Kosztáczky B, Paragh G, Seres I, Zs?́ros E, Kónya G & Paragh G 2007 The concentration dependent biphasic effect of leptin on endogenous cholesterol synthesis in human monocytes. Peptides 28 2081-2083.
4. Baranowski M 2008 Biological role of liver X receptors. Journal of Physiology and Pharmacology 59 31-55.
5. Bełtowski J, Wójcicka G & Jamroz A 2003 Leptin decreases plasma paraoxonase 1 (PON1) activity and induces oxidative stress: the possible novel mechanism for proatherogenic effect of chronic hyperleptinemia. Atherosclerosis 170 21-29.
6. Bełtowski J, Jamroz-Wiśniewska A, Borkowska E & Wójcicka G 2005 Differential effect of antioxidant treatment on plasma and tissue paraoxonase activity in hyperleptinemic rats. Pharmacological Research 51 523-532.
7. Billecke S, Draganov D, Counsell R, Stetson P,Watson C, Hsu C & La Du BN 2000 Human serum paraoxonase (PON1) isozymes Q and R hydrolyze lactones and cyclic carbonate esters. Drug Metabolism and Disposition 28 1335-1342.
8. Bodary PF, Gu S, Shen Y, Hasty AH, Buckler JM & Eitzman DT 2005 Recombinant leptin promotes atherosclerosis and thrombosis in apolipo-protein E-deficient mice. Arteriosclerosis, Thrombosis, and Vascular Biology 25 e119-e122.
9. Bouloumie A, Marumo T, Lafontan M & Busse R 1999 Leptin induces oxidative stress in human endothelial cells. FASEB Journal 13 1231-1238.
10. Brown AJ 2009 24(S),25-epoxycholesterol: a messenger for cholesterol homeostasis. International Journal of Biochemistry and Cell Biology 41 744-747.
11. Chang L, Zhang Z, Li W, Dai J, Guan Y & Wang X 2007 Liver-X-receptor activator prevents homocysteine-induced production of IgG antibodies from murine B lymphocytes via the ROS-NF-κB pathway. Biochemical and Biophysical Research Communications 357 772-778.
12. Chiba T, Shinozaki S, Nakazawa T, Kawakami A, Ai M, Kaneko E, Kitagawa M, Kondo K, Chait A & Shimokado K 2008 Leptin deficiency suppresses progression of atherosclerosis in apoE-deficient mice. Atherosclerosis 196 68-75.
13. Considine RV, Sinha MK, Heiman ML, Aidas Kriauciunas A, Stephens TW, Nyce MR, Ohannesian JP, Marco CC, McKee LJ, Bauer TL et al. 1996 Serum immunoreactive-leptin concentrations in normal-weight and obese humans. New England Journal of Medicine 334 292-295.
14. Dellas C, Schäfer K, Rohm I, Lankeit M, Ellrott T, Faustin V, Riggert J, Hasenfuss G & Konstantinides S 2008 Absence of leptin resistance in platelets from morbidly obese individuals may contribute to the increased thrombosis risk in obesity. Thrombosis and Haemostasis 100 1123-1129.
15. Delvecchio CJ & Capone JP 2008 Protein kinase C alpha modulates liver X receptor alpha transactivation. Journal of Endocrinology 197 121-130.
16. Domagala TB, £acinski M, Trzeciak WH, Mackness B, Mackness MI & Jakubowski H 2006 The correlation of homocysteine-thiolactonase activity of the paraoxonase (PON1) protein with coronary heart disease status. Cellular and Molecular Biology 52 4-10.
17. Farooqi IS & O'Rahilly S 2009 Leptin: a pivotal regulator of human energy homeostasis. American Journal of Clinical Nutrition 89 980S-984S.
18. Ferretti G, Baccetti T, Moroni C, Vignini A, Nanetti L & Curatola G 2004 Effect of homocysteinylation of low density lipoproteins on lipid peroxidation of human endothelial cells. Journal of Cellular Biochemistry 92 351-360.
19. Ferretti G, Baccetti T, Moroni C, Savino S, Liuzzi A, Balzola F & Bicchiega V 2005 Paraoxanase activity in high density lipoproteins: Comparision between healthy and obese females. Journal of Clinical Endocrinology and Metabolism 90 1728-1733.
20. Ferretti G, Bacchetti T, Rabini RA, Vignini A, Nanetti L, Moroni C & Mazzanti L 2006 Homocysteinylation of low-density lipoproteins (LDL) from subjects with type 1 diabetes: effect on oxidative damage of human endothelial cells. Diabetic Medicine 2 808-813.
21. Fiévet C & Staels B 2009 Liver X receptor modulators: effects on lipid metabolism and potential use in the treatment of atherosclerosis. Biochemical Pharmacology 77 1316-1327.
22. Frühbeck G 2006 Intracellular signalling pathways activated by leptin. Biochemical Journal 393 7-20.
23. Gouédard C, Koum-Besson N, Barouki R & Morel Y 2003 Opposite regulation of the human paraoxonase-1 gene PON-1 by fenofibrate and statins. Molecular Pharmacology 63 945-956.
24. Houck KA, Borchert KM, Hepler CD, Thomas JS, Bramlett KS, Michael LF & Burris TP 2004 T0901317 is a dual LXR/FXR agonist. Molecular Genetics and Metabolism 83 184-187.
25. Jakubowski H 2000 Calcium-dependent human serum homocysteine thiolactone hydrolase. A protective mechanism against protein N-homocysteinylation. Journal of Biological Chemistry 275 3957-3962.
26. Jakubowski H 2005 Anti-N-homocysteinylated protein autoantibodies and cardiovascular disease. Clinical Chemistry and Laboratory Medicine 43 1011-1014.
27. Jakubowski H 2008 The pathophysiological hypothesis of homocysteine thiolactone-mediated vascular disease. Journal of Physiology and Pharmacology 59 155-167.
28. Jakubowski H, Zhang L, Bardeguez A & Aviv A 2000 Homocysteine thiolactone and protein homocysteinylation in human endothelial cells: implications for atherosclerosis. Circulation Research 87 45-51.
29. Jakubowski H, Ambrosius WT & Pratt JH 2001 Genetic determinants of homocysteine thiolactonase activity in humans: implications for atherosclerosis. FEBS Letters 491 35-39.
30. Jakubowski H, Boers GH & Strauss KA 2008 Mutations in cystathionine beta-synthase or methylenetetrahydrofolate reductase gene increase N-homocysteinylated protein levels in humans. FASEB Journal 22 4071-4076.
31. Jakubowski H, Perla-Kaján J, Finnell RH, Cabrera RM, Wang H, Gupta S, Kruger WD, Kraus JP & Shih DM 2009 Genetic or nutritional disorders in homocysteine or folate metabolism increase protein N-homocysteinylation in mice. FASEB Journal 23 1721-1727.
32. James RW 2006 A long and winding road: defining the biological role and clinical importance of paraoxonases. Clinical Chemistry and Laboratory Medicine 44 1052-1059.
33. Janowski BA, Grogan MJ, Jones SA, Wisely GB, Kliewer SA, Corey EJ & Mangelsdorf DJ 1999 Structural requirements of ligands for the oxysterol liver X receptors LXRα and LXRβ. PNAS 96 266-271.
34. Khersonsky O & Tawfik DS 2005 Structure-reactivity studies of serum paraoxonase PON1 suggest that its native activity is lactonase. Biochemistry 44 6371-6682.
35. Knudson JD, Payne GA, Borbouse L & Tune JD 2008 Leptin and mechanisms of endothelial dysfunction and cardiovascular disease. Current Hypertension Reports 10 434-439.
36. Koh KK, Park SM & Quon MJ 2008 Leptin and cardiovascular disease: response to therapeutic interventions. Circulation 117 3238-3249.
37. Korda M, Kubant R, Patton S & Malinski T 2008 Leptin-induced endothelial dysfunction in obesity. American Journal of Physiology. Heart and Circulatory Physiology 295 H1514-H1521.
38. Mackness B, Durrington P, McElduff P, Yarnell J, Azam N, Watt M & Mackness M 2003 Low paraoxonase activity predicts coronary events in the Caerphilly Prospective Study. Circulation 107 2775-2779.
39. Mackness B, Quarck R, Verreth W, Mackness M & Holvoet P 2006 Human paraoxonase-1 overexpression inhibits atherosclerosis in a mouse model of metabolic syndrome. Arteriosclerosis, Thrombosis, and Vascular Biology 26 1545-1550.
40. Nguyen SD, Hung ND, Cheon-Ho P, Ree KM & Dai-Eun S 2009 Oxidative inactivation of lactonase activity of purified human paraoxonase 1 (PON1). Biochimica et Biophysica Acta 1790 155-160.
41. Perla-Kajan J, Stanger O, Luczak M, Ziólkowska A, Malendowicz LK, Twardowski T, Lhotak S, Austin RC & Jakubowski H 2008 Immunohistochemical detection of N-homocysteinylated proteins in humans and mice. Biomedicine & Pharmacotherapy 62 473-479.
42. Perna AF, Satta E, Acanfora F, Lombardi C, Ingrosso D & De Santo NG 2006 Increased plasma protein homocysteinylation in hemodialysis patients. Kidney International 69 869-876.
43. Riederer M, ErwaW, Zimmermann R, Frank S & Zechner R 2009 Adipose tissue as a source of nicotinamide N-methyltransferase and homocysteine. Atherosclerosis 204 412-417.
44. Sattar N, Wannamethee G, Sarwar N, Chernova J, Lawlor DA, Kelly A, Wallace AM, Danesh J & Whincup PH 2009 Leptin and coronary heart disease: prospective study and systematic review. Journal of the American College of Cardiology 53 167-175.
45. Sauls DL, Lockhart E,Warren ME, Lenkowski A, Wilhelm SE & Hoffman M 2006 Modification of fibrinogen by homocysteine thiolactone increases resistance to fibrinolysis: a potential mechanism of the thrombotic tendency in hyperhomocysteinemia. Biochemistry 45 2480-2487.
46. Shih DM, Gu L, Xia YR, Navab M, Li WF, Hama S, Castellani LW, Furlong CE, Costa LG, Fogelman AM et al. 1998 Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 394 284-287.
47. Shih DM, Kast-Woelbern HR, Wong J, Xia YR, Edwards PA & Lusis AJ 2006 A role for FXR and human FGF-19 in the repression of paraoxonase-1 gene expression by bile acids. Journal of Lipid Research 47 384-392.
48. Singh P, Hoffmann M,Wolk R, Shamsuzzaman AS & Somers VK 2007 Leptin induces C-reactive protein expression in vascular endothelial cells. Arteriosclerosis, Thrombosis, and Vascular Biology 27 e302-e307.
49. Söderberg S, Stegmayr B, Ahlbeck-Glader C, Slunga-Birgander L, Ahrén B & Olsson T 2003 High leptin levels are associated with stroke. Cerebrovascular Diseases 15 63-69.
50. Söderberg S, Colquhoun D, Keech A, Yallop J, Barnes EH, Pollicino C, Simes J, Tonkin AM & Nestel P 2009 Leptin, but not adiponectin, is a predictor of recurrent cardiovascular events in men: results from the LIPID study. International Journal of Obesity 33 123-130.
51. Taleb S, Herbin O, Ait-Oufella H, Verreth W, Gourdy P, Barateau V, Merval R, Esposito B, Clément K, Holvoet P et al. 2007 Defective leptin/leptin receptor signaling improves regulatory T cell immune response and protects mice from atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology 27 2691-2698.
52. Terasaka N, Hiroshima A, Koieyama T, Ubukata N, Morikawa Y, Nakai D & Inaba T 2003 T-0901317, a synthetic liver X receptor ligand, inhibits development of atherosclerosis in LDL receptor-deficient mice. FEBS Letters 536 6-11.
53. Tward A, Xia YR, Wang XP, Shi YS, Park C, Castellani LW, Lusis AJ & Shih DM 2002 Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice. Circulation 106 484-490.
54. Vignini A, Nanetti L, Bacchetti T, Ferretti G, Curatola G & Mazzanti L 2004 Modification induced by homocysteine and low-density lipoprotein on human aortic endothelial cells: an in vitro study. Journal of Clinical Endocrinology and Metabolism 89 4558-4561.
55. Yang X, Gao Y, Zhou J, Zhen Y, Yang Y, Wang J, Song L, Liu Y, Xu H, Chen Z et al. 2006 Plasma homocysteine thiolactone adducts associated with risk of coronary heart disease. Clinica Chimica Acta 364 230-234.
56. Zeidan A, Purdham DM, Rajapurohitam V, Javadov S, Chakrabarti S & Karmazyn M 2005 Leptin induces vascular smooth muscle cell hypertrophy through angiotensin II- and endothelin-1-dependent mechanisms and mediates stretch-induced hypertrophy. Journal of Pharmacology and Experimental Therapeutics 315 1075-1084.